Market Cap: $183.29M
CL
Compugen Ltd.
CGEN
NASDAQ (NASDAQ Global Market)USD
Market Cap: $183.29M
Compugen Ltd (Ticker: CGEN), a clinical-stage cancer immunotherapy company, is making significant strides in the fight against relapsed platinum-sensitive ovarian cancer. Recently, the company present…
At the forefront of innovation in cancer treatment, Compugen Inc. demonstrates its significant advances in the field of immuno-oncology at the recent Needham & Company Healthcare Conference. The compa…
Compugen's Strategic Advances in Therapeutic Development Compugen, a biopharmaceutical firm focused on pioneering therapeutic solutions, releases its Q4 earnings report, highlighting pivotal advanceme…
Compugen Consolidates Growth with Strong Q4 Report Compugen (NASDAQ:CGEN) demonstrates resilience and operational progress in its recent Q4 earnings report, released on March 2, 2026. The report revea…
Compugen’s Clinical Advancements Spotlighted in Q4 Earnings Report On March 2, 2026, Compugen (NASDAQ:CGEN) announces its Q4 earnings report, showcasing significant advancements within its clinical tr…
Compugen appoints veteran biotech executive to strengthen board capacity Board addition aims to accelerate clinical execution and partnerships Compugen names Michele Holcomb, Ph.D., to its board as an…
New board addition targets development and partnering execution Compugen appoints Michele Holcomb, Ph.D., as an independent director effective Feb. 11, 2026, in a move the company says is intended to…
Compugen Secures Strategic Agreement with AstraZeneca to Enhance Financial Position Compugen Ltd. solidifies its financial footing through a strategic partnership with AstraZeneca, which is pivotal fo…
Compugen Secures Strategic Partnership with AstraZeneca to Enhance Financial Stability and Support Immuno-Oncology Pipeline Compugen Ltd. has recently announced a significant non-dilutive strategic ag…
Strategic Alliance Enhances Compugen's Financial Stability and Growth Potential Compugen Ltd. solidifies its financial standing through a non-dilutive strategic agreement with AstraZeneca, focusing on…
Compugen Advances in Immuno-Oncology with New Therapeutic Targets Compugen, a biotechnology company specializing in immuno-oncology, unveils its latest research findings that highlight novel therapeut…
Compugen: Strategic Focus on Operational Efficiency Amidst Earnings Reports Compugen is navigating the competitive landscape of biopharmaceutical companies, particularly as several industry peers prep…
Compugen's Strategic Approach in a Competitive Biopharmaceutical Landscape Compugen continues to solidify its position within the biopharmaceutical industry by focusing on the development of innovativ…
Compugen Expands Its Reach with New Eastern Canada Technology Centre Compugen Inc., recognized as Canada’s largest privately-owned IT services provider, inaugurates its Eastern Canada Technology Centr…
Compugen Advances Cancer Immunotherapy with Upcoming Presentation Compugen Ltd., a clinical-stage cancer immunotherapy company based in Holon, Israel, reaches a significant milestone as it prepares to…
Compugen Advances Cancer Immunotherapy with COM503 Presentation Compugen Ltd., a clinical-stage cancer immunotherapy company based in Holon, Israel, reaches a significant milestone with its first huma…
Compugen Strengthens Cybersecurity Footprint with SynerSolutions Acquisition On November 4, 2024, Compugen Inc. announces its acquisition of SynerSolutions Technologies Inc., a key player in cybersecu…